MUSTANG BIO, INC. MBIO
Pharmaceutical Preparations · CIK 0001680048 · Fiscal year ends 1231
Revenue
—Unavailable
Fiscal year ended 2025-12-31Operating income
-$2.43M
Fiscal year ended 2025-12-31Free cash flow
—Unavailable
Fiscal year ended 2025-12-31Valuation, from the filing
| Public float | $3.20M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|
| Float / equity | 0.3× | A lower bound on the multiple, because affiliate holdings are excluded. |
|---|
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
MUSTANG BIO, INC. (MBIO) reported net income of -$1.92M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from MUSTANG BIO, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
MUSTANG BIO, INC. income by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|
| Revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Cost of revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Gross profit | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Operating income | -$2.43M | -$16.24M | -$49.26M | -$76.16M | -$66.72M | -$56.81M | -$45.88M | -$31.22M | -$31.78M | -$11.36M |
|---|
| Net income | -$1.92M | -$15.75M | -$51.60M | -$77.52M | -$66.37M | -$60.02M | -$46.39M | -$30.66M | -$31.29M | -$12.65M |
|---|
| Research & development | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | $2.10M | $100.00K | $2.00M |
|---|
| Weighted-average diluted shares | shares 4.91M | —Unavailable | —Unavailable | shares 7.68M | shares 87.89M | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Pretax income | -$1.92M | -$15.75M | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Income tax expense | $27.00K | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Diluted EPS | $-0.39 | $-38.57 | $-299.95 | $-10.09 | $-0.76 | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Selling, general & administrative | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| General & administrative | $3.95M | $4.14M | $9.69M | $12.21M | $11.02M | $9.50M | $9.57M | $6.76M | $11.41M | $2.82M |
|---|
| Selling & marketing | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Balance
MUSTANG BIO, INC. balance by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|
| Cash & equivalents | $17.27M | $6.84M | $6.23M | $75.66M | $109.62M | $97.80M | $61.41M | $16.47M | —Unavailable | $27.50M |
|---|
| Total assets | $17.59M | $9.31M | $17.74M | $92.42M | $125.17M | $109.90M | $73.44M | $42.75M | $63.49M | $27.50M |
|---|
| Current assets | $17.59M | $8.61M | $11.35M | $78.85M | $111.71M | $99.53M | $63.06M | $35.12M | $61.36M | $27.50M |
|---|
| Total liabilities | $8.06M | $13.18M | $17.62M | $46.15M | $12.77M | $11.46M | $21.79M | $6.36M | $3.66M | $3.22M |
|---|
| Current liabilities | $7.91M | $12.61M | $15.37M | $15.11M | $10.82M | $9.52M | $7.77M | $5.62M | $3.61M | $3.22M |
|---|
| Total equity incl. NCI | $9.53M | -$3.87M | $123.00K | $46.27M | $112.40M | $98.44M | $51.65M | $36.40M | $59.83M | $24.28M |
|---|
| Temporary (mezzanine) equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Inventory | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Accounts receivable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Goodwill | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Long-term debt | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Accounts payable | $3.51M | $7.46M | $6.32M | $6.83M | $3.51M | $3.52M | $1.88M | $1.39M | —Unavailable | —Unavailable |
|---|
Cash flow
MUSTANG BIO, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|
| Operating cash flow | -$5.26M | -$11.41M | -$49.48M | -$65.07M | -$53.67M | -$37.32M | -$33.58M | -$19.24M | -$12.95M | -$4.13M |
|---|
| Capital expenditures | —Unavailable | $0 | $64.00K | $2.71M | $3.99M | $1.92M | $2.34M | $6.87M | $424.00K | —Unavailable |
|---|
| Investing cash flow | $1.16M | $0 | $5.89M | -$2.95M | -$5.37M | -$4.41M | $13.91M | $557.00K | -$29.05M | $0 |
|---|
| Financing cash flow | $14.53M | $11.26M | -$26.08M | $34.06M | $70.85M | $78.12M | $65.12M | $181.00K | $49.98M | $31.63M |
|---|
| Net change in cash | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | -$18.51M | $7.98M | $27.50M |
|---|
| Stock-based compensation | $129.00K | -$450.00K | $568.00K | $2.28M | $3.31M | $2.99M | $2.66M | $4.96M | $2.01M | $0 |
|---|
| Common dividends paid | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Common share repurchases | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Depreciation & amortization | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Derived
MUSTANG BIO, INC. derived by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|
| Free cash flow | —Unavailable | —Unavailable | -$49.54M | -$67.78M | -$57.65M | -$39.24M | -$35.93M | -$26.11M | -$13.37M | —Unavailable |
|---|
| Gross margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Operating margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| FCF margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| SBC / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Current ratio | —Unavailable | 0.68x | 0.74x | 5.22x | 10.33x | 10.46x | 8.12x | 6.25x | 16.99x | 8.53x |
|---|
| Revenue YoY growth | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Net margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| R&D / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| CapEx / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Long-term debt / equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Effective tax rate | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MBIO in the interactive workspace to inspect any figure back to its filing.
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.